Nanodrug regulates lactic acid metabolism to reprogram the immunosuppressive tumor microenvironment for enhanced cancer immunotherapy

• Published in: Biomaterials science 2022-07, Vol.1 (14), p.3892-39
• Main Authors: Tian, Li-Rong, Lin, Min-Zhao, Zhong, Hui-Hai, Cai, Yu-Jun, Li, Bo, Xiao, Ze-Cong, Shuai, Xin-Tao
• Format: Article
• Language: English
• Subjects: Efflux; Immune system; Immunosuppression; Immunotherapy; In vivo methods and tests; Lactic acid; Lymphocytes; Macrophages; Metabolism; Tumors
• ISSN: 2047-4830; 2047-4849
• DOI: 10.1039/d2bm00650b

A majority of cancers fail to respond to immunotherapy due to the immunosuppressive tumor microenvironment (TME), and metabolic regulation of the TME has been a promising strategy to improve immunotherapy. Lactate is a key metabolic player in tumor immune response since its excess secretion aggravates tumor immune escape by favoring the polarization of tumor-associated macrophages (TAMs) to an immunosuppressive phenotype meanwhile impeding the tumor infiltration of the cytotoxic T lymphocyte. Here, we proposed a metabolic reprogramming mechanism to ameliorate tumor immunosuppression by using lonidamine and syrosingopine incorporated liposomes (L@S/L) to regulate lactate production and efflux. Concretely, lonidamine reduced lactate production by affecting the glycolytic metabolic pathway while syrosingopine decreased lactate efflux by inhibiting the key protein expression of the lactate transporter MCT-4. Consequently, both the drugs synergistically normalize the pH of the TME to overcome the tumor immunosuppressive microenvironment. In vivo studies demonstrated that the decreased extracellular lactate preferentially polarized TAMs to the M1 phenotype, simultaneously increased the proportion of NK cells and reduced the number of Treg cells. These results validated an efficient tumor immunotherapy in the breast cancer model. This new strategy of lactic acid metabolism regulation is proposed to operate in concert with immune modulation in the TME, which shows great potential for immunotherapy of immunologically "cold" tumors. A novel strategy of tumor microenvironment reprogramming by Intra/extracellular lactic acid exhausting for antitumor immune therapy.